Evolution of targeted therapies for thyroid carcinoma.
EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA. Trans Am Clin Climatol Assoc. 2019;130:255-265 Authors: Sherman SI Abstract Although treatment options for patients with advanced and metastatic thyroid carcinoma were historically limited, developments in the past 15 years in understanding the pathogenesis of these malignancies have permitted identification of novel targeted therapies to improve outcomes. Five individual drugs and one combination therapy have achieved regulatory approval since 2011, all showing improvements in progression-free survival or high response rates. More selective targeting of mutated oncogenic kinases is leading to increasing efficacy with fewer toxicities, at least in early human trials. Collaborations among endocrinologists, medical oncologists, and patients are making advances possible, where such developments appeared impossible merely 15 years ago. PMID: 31516190 [PubMed - in process]
Conditions: Papillary Thyroid Cancer; Papillary Thyroid Microcarcinoma Intervention: Device: RFA Sponsor: Mayo Clinic Not yet recruiting
AbstractPurposeWe assessed the optimal time for intact parathyroid hormone (iPTH) measurement for early detection of post-total thyroidectomy (TT) hypocalcemia in patients with papillary thyroid carcinoma (PTC).MethodsIn this single-center prospective cohort study, 143 patients who underwent TT with central neck dissection with or without lateral neck dissection for PTC were included. Biochemical profiles including iPTH, corrected total calcium, and ionized calcium within 24 h after surgery were analyzed.ResultsThe 4-h postoperative iPTH was the most reliable predictor of post-TT transient or permanent hypoparathyroidism (...
Thyroid, Ahead of Print.
ConclusionLiterature published in the last decade offers data that support adjuvant postoperative RIT in DTC patients with a tumor diameter exceeding 1 cm. Therefore, at least until randomized prospective studies prove otherwise, the prescription of adjuvant I-131 treatment to all DTC patients with a primary tumor diameter exceeding 1 cm remains a reasonable option.
The long-term health-related quality-of-life implications of treating low-risk differentiated thyroid cancer with total thyroidectomy or hemithyroidectomy is important to patients but remains poorly understood.
AbstractHow to differentiate thyroid cancer nodules from a large number of benign nodules is always a challenging subject for clinicians. This paper proposes a novel Sal-deel network model to achieve the classification and diagnosis of thyroid cancer, which can simulate visual attention mechanism. The Sal-deep network introduces saliency map as an additional information on the deep residual network, which selectively enhances the feature extracted from different regions according to the mask map. Sal-deep network can work effectively for the benchmark networks with different data sets and different structures, and it is a ...
Abstract AP-1 is a dimeric complex that is composed of JUN, FOS, ATF and MAF protein families. FOS-related antigen 1 (FRA1) which encoded by FOSL1 gene, belongs to the FOS protein family, and mainly forms an AP-1 complex with the protein of the JUN family to exert an effect. Regulation of FRA1 occurs at levels of transcription and post-translational modification, and phosphorylation is the major post-translational modification. FRA1 is mainly regulated by the mitogen-activated protein kinases signaling pathway and is degraded by ubiquitin-independent proteasomes. FRA1 can affect biological functions, such as tumor...
ConclusionsAltogether, the findings of the current study suggest that down-regulated miR-875-5p expression could promote its target gene NIS to increase radioiodine uptake in PDTC, constituting a preventive strategy against PDTC.
ConclusionPulmonary metastasectomy for lesions originating from head and neck provides good long-term survival. Histological subtype was the only statistically significant prognostic factor.